Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Flow cytometry in drug discovery and development [[electronic resource] /] / edited by Virginia M. Litwin, Philip Marder
| Flow cytometry in drug discovery and development [[electronic resource] /] / edited by Virginia M. Litwin, Philip Marder |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2011 |
| Descrizione fisica | 1 online resource (370 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) |
LitwinVirginia
MarderPhilip |
| Soggetto topico |
Flow cytometry
Drugs - Design |
| ISBN |
0-470-92278-8
1-283-91610-X 0-470-91008-9 0-470-91007-0 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. Introduction / Philip Marder and Virginia Litwin -- pt. 2. Flow cytometry in the drug development process / Virginia Litwin and Philip Marder -- pt. 3. Validation and regulatory compliance / Virginia Litwin and Philip Marder -- pt. 4. Future directions / Virginia Litwin and Philip Marder. |
| Record Nr. | UNINA-9910831051303321 |
| Hoboken, N.J., : Wiley, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Flow cytometry in drug discovery and development [[electronic resource] /] / edited by Virginia M. Litwin, Philip Marder
| Flow cytometry in drug discovery and development [[electronic resource] /] / edited by Virginia M. Litwin, Philip Marder |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2011 |
| Descrizione fisica | 1 online resource (370 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) |
LitwinVirginia
MarderPhilip |
| Soggetto topico |
Flow cytometry
Drugs - Design |
| ISBN |
0-470-92278-8
1-283-91610-X 0-470-91008-9 0-470-91007-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. 1. Introduction / Philip Marder and Virginia Litwin -- pt. 2. Flow cytometry in the drug development process / Virginia Litwin and Philip Marder -- pt. 3. Validation and regulatory compliance / Virginia Litwin and Philip Marder -- pt. 4. Future directions / Virginia Litwin and Philip Marder. |
| Record Nr. | UNINA-9910841597203321 |
| Hoboken, N.J., : Wiley, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke
| Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke |
| Pubbl/distr/stampa | Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016 |
| Descrizione fisica | 1 online resource (527 p.) |
| Disciplina | 615.19 |
| Collana | Methods and Principles in Medicinal Chemistry |
| Soggetto topico |
Drug development
Drugs - Design Ligands (Biochemistry) Drug Discovery LIgands |
| ISBN |
3-527-68362-3
3-527-68360-7 3-527-68361-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Fragment-based Drug Discovery: Lessons and Outlook; Contents; Contributors; Preface; A Personal Foreword; Part I: The Concept of Fragment-based Drug Discovery; 1. The Role of Fragment-based Discovery in Lead Finding; 1.1 Introduction; 1.2 What is FBLD?; 1.3 FBLD: Current Practice; 1.3.1 Using Fragments: Conventional Targets; 1.3.2 Using Fragments: Unconventional Targets; 1.4 What do Fragments Bring to Lead Discovery?; 1.5 How did We Get Here?; 1.5.1 Evolution of the Early Ideas and History; 1.5.2 What has Changed Since the First Book was Published in 2006?
1.6 Evolution of the Methods and Their Application Since 20051.6.1 Developments in Fragment Libraries; 1.6.2 Fragment Hit Rate and Druggability; 1.6.3 Developments in Fragment Screening; 1.6.4 Ways of Evolving Fragments; 1.6.5 Integrating Fragments Alongside Other Lead-Finding Strategies; 1.6.6 Fragments Can be Selective; 1.6.7 Fragment Binding Modes; 1.6.8 Fragments, Chemical Space, and Novelty; 1.7 Current Application and Impact; 1.8 Future Opportunities; References; 2. Selecting the Right Targets for Fragment-Based Drug Discovery; 2.1 Introduction 2.2 Properties of Targets and Binding Sites2.3 Assessing Druggability; 2.4 Properties of Ligands and Drugs; 2.5 Case Studies; 2.5.1 Case Study 1: Inhibitors of Apoptosis Proteins (IAPs); 2.5.2 Case Study 2: HCV-NS3; 2.5.3 Case Study 3: PKM2; 2.5.4 Case Study 4: Soluble Adenylate Cyclase; 2.6 Conclusions; References; 3. Enumeration of Chemical Fragment Space; 3.1 Introduction; 3.2 The Enumeration of Chemical Space; 3.2.1 Counting and Sampling Approaches; 3.2.2 Enumeration of the Chemical Universe Database GDB; 3.2.3 GDB Contents; 3.3 Using and Understanding GDB; 3.3.1 Drug Discovery 3.3.2 The MQN System3.3.3 Other Fingerprints; 3.4 Fragments from GDB; 3.4.1 Fragment Replacement; 3.4.2 Shape Diversity of GDB Fragments; 3.4.3 Aromatic Fragments from GDB; 3.5 Conclusions and Outlook; Acknowledgment; References; 4. Ligand Efficiency Metrics and their Use in Fragment Optimizations; 4.1 Introduction; 4.2 Ligand Efficiency; 4.3 Binding Thermodynamics and Efficiency Indices; 4.4 Enthalpic Efficiency Indices; 4.5 Lipophilic Efficiency Indices; 4.6 Application of Efficiency Indices in Fragment-Based Drug Discovery Programs; 4.7 Conclusions; References Part II: Methods and Approaches for Fragment-based Drug Discovery5. Strategies for Fragment Library Design; 5.1 Introduction; 5.2 Aims; 5.3 Progress; 5.3.1 BDDP Fragment Library Design: Maximizing Diversity; 5.3.2 Assessing Three-Dimensionality; 5.3.3 3DFrag Consortium; 5.3.4 Commercial Fragment Space Analysis; 5.3.5 BDDP Fragment Library Design; 5.3.6 Fragment Complexity; 5.3.6.1 Diversity-Oriented Synthesis-Derived Fragment-Like Molecules; 5.4 Future Plans; 5.5 Summary; 5.6 Key Achievements; References 6. The Synthesis of Biophysical Methods In Support of Robust Fragment-Based Lead Discovery |
| Record Nr. | UNINA-9910137167803321 |
| Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke
| Fragment-based drug discovery : lessons and outlook / / edited by Daniel A. Erlanson and Wolfgang Jahnke |
| Pubbl/distr/stampa | Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016 |
| Descrizione fisica | 1 online resource (527 p.) |
| Disciplina | 615.19 |
| Collana | Methods and Principles in Medicinal Chemistry |
| Soggetto topico |
Drug development
Drugs - Design Ligands (Biochemistry) Drug Discovery LIgands |
| ISBN |
3-527-68362-3
3-527-68360-7 3-527-68361-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Fragment-based Drug Discovery: Lessons and Outlook; Contents; Contributors; Preface; A Personal Foreword; Part I: The Concept of Fragment-based Drug Discovery; 1. The Role of Fragment-based Discovery in Lead Finding; 1.1 Introduction; 1.2 What is FBLD?; 1.3 FBLD: Current Practice; 1.3.1 Using Fragments: Conventional Targets; 1.3.2 Using Fragments: Unconventional Targets; 1.4 What do Fragments Bring to Lead Discovery?; 1.5 How did We Get Here?; 1.5.1 Evolution of the Early Ideas and History; 1.5.2 What has Changed Since the First Book was Published in 2006?
1.6 Evolution of the Methods and Their Application Since 20051.6.1 Developments in Fragment Libraries; 1.6.2 Fragment Hit Rate and Druggability; 1.6.3 Developments in Fragment Screening; 1.6.4 Ways of Evolving Fragments; 1.6.5 Integrating Fragments Alongside Other Lead-Finding Strategies; 1.6.6 Fragments Can be Selective; 1.6.7 Fragment Binding Modes; 1.6.8 Fragments, Chemical Space, and Novelty; 1.7 Current Application and Impact; 1.8 Future Opportunities; References; 2. Selecting the Right Targets for Fragment-Based Drug Discovery; 2.1 Introduction 2.2 Properties of Targets and Binding Sites2.3 Assessing Druggability; 2.4 Properties of Ligands and Drugs; 2.5 Case Studies; 2.5.1 Case Study 1: Inhibitors of Apoptosis Proteins (IAPs); 2.5.2 Case Study 2: HCV-NS3; 2.5.3 Case Study 3: PKM2; 2.5.4 Case Study 4: Soluble Adenylate Cyclase; 2.6 Conclusions; References; 3. Enumeration of Chemical Fragment Space; 3.1 Introduction; 3.2 The Enumeration of Chemical Space; 3.2.1 Counting and Sampling Approaches; 3.2.2 Enumeration of the Chemical Universe Database GDB; 3.2.3 GDB Contents; 3.3 Using and Understanding GDB; 3.3.1 Drug Discovery 3.3.2 The MQN System3.3.3 Other Fingerprints; 3.4 Fragments from GDB; 3.4.1 Fragment Replacement; 3.4.2 Shape Diversity of GDB Fragments; 3.4.3 Aromatic Fragments from GDB; 3.5 Conclusions and Outlook; Acknowledgment; References; 4. Ligand Efficiency Metrics and their Use in Fragment Optimizations; 4.1 Introduction; 4.2 Ligand Efficiency; 4.3 Binding Thermodynamics and Efficiency Indices; 4.4 Enthalpic Efficiency Indices; 4.5 Lipophilic Efficiency Indices; 4.6 Application of Efficiency Indices in Fragment-Based Drug Discovery Programs; 4.7 Conclusions; References Part II: Methods and Approaches for Fragment-based Drug Discovery5. Strategies for Fragment Library Design; 5.1 Introduction; 5.2 Aims; 5.3 Progress; 5.3.1 BDDP Fragment Library Design: Maximizing Diversity; 5.3.2 Assessing Three-Dimensionality; 5.3.3 3DFrag Consortium; 5.3.4 Commercial Fragment Space Analysis; 5.3.5 BDDP Fragment Library Design; 5.3.6 Fragment Complexity; 5.3.6.1 Diversity-Oriented Synthesis-Derived Fragment-Like Molecules; 5.4 Future Plans; 5.5 Summary; 5.6 Key Achievements; References 6. The Synthesis of Biophysical Methods In Support of Robust Fragment-Based Lead Discovery |
| Record Nr. | UNINA-9910676628503321 |
| Wiesbaden, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro
| Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro |
| Pubbl/distr/stampa | Chichester, U.K., : John Wiley & Sons, 2008 |
| Descrizione fisica | 1 online resource (297 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) |
ZartlerEdward
ShapiroMichael (Michael J.) |
| Soggetto topico |
Drug development
Drugs - Design Ligands (Biochemistry) |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-34275-4
9786612342752 0-470-72155-3 0-470-72156-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Fragment-Based Drug Discovery; Contents; List of Contributors; 1 Introduction to Fragment-based Drug Discovery; 2 Designing a Fragment Process to Fit Your Needs; 3 Assembling a Fragment Library; 4 Practical Aspects of Using NMR in Fragment-based Screening; 5 Application of Protein-Ligand NOE Matching to the Rapid Evaluation of Fragment Binding Poses; 6 Target-immobilized NMR Screening: Validation and Extension to Membrane Proteins; 7 In Situ Fragment-based Medicinal Chemistry: Screening by Mass Spectrometry; 8 Computational Approaches to Fragment and Substructure Discovery and Evaluation
9 Virtual Fragment Scanning: Current Trends, Applications and Web-based Tools10 Capture Methods for Fragment-based Discovery; 11 Identification of High-affinity -Secretase Inhibitors Using Fragment-based Lead Generation; Index |
| Record Nr. | UNINA-9910144402103321 |
| Chichester, U.K., : John Wiley & Sons, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro
| Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro |
| Pubbl/distr/stampa | Chichester, U.K., : John Wiley & Sons, 2008 |
| Descrizione fisica | 1 online resource (297 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) |
ZartlerEdward
ShapiroMichael (Michael J.) |
| Soggetto topico |
Drug development
Drugs - Design Ligands (Biochemistry) |
| ISBN |
1-282-34275-4
9786612342752 0-470-72155-3 0-470-72156-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Fragment-Based Drug Discovery; Contents; List of Contributors; 1 Introduction to Fragment-based Drug Discovery; 2 Designing a Fragment Process to Fit Your Needs; 3 Assembling a Fragment Library; 4 Practical Aspects of Using NMR in Fragment-based Screening; 5 Application of Protein-Ligand NOE Matching to the Rapid Evaluation of Fragment Binding Poses; 6 Target-immobilized NMR Screening: Validation and Extension to Membrane Proteins; 7 In Situ Fragment-based Medicinal Chemistry: Screening by Mass Spectrometry; 8 Computational Approaches to Fragment and Substructure Discovery and Evaluation
9 Virtual Fragment Scanning: Current Trends, Applications and Web-based Tools10 Capture Methods for Fragment-based Discovery; 11 Identification of High-affinity -Secretase Inhibitors Using Fragment-based Lead Generation; Index |
| Record Nr. | UNINA-9910830794403321 |
| Chichester, U.K., : John Wiley & Sons, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro
| Fragment-based drug discovery [[electronic resource] ] : a practical approach / / editors, Edward R. Zartler, Michael J. Shapiro |
| Pubbl/distr/stampa | Chichester, U.K., : John Wiley & Sons, 2008 |
| Descrizione fisica | 1 online resource (297 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) |
ZartlerEdward
ShapiroMichael (Michael J.) |
| Soggetto topico |
Drug development
Drugs - Design Ligands (Biochemistry) |
| ISBN |
1-282-34275-4
9786612342752 0-470-72155-3 0-470-72156-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Fragment-Based Drug Discovery; Contents; List of Contributors; 1 Introduction to Fragment-based Drug Discovery; 2 Designing a Fragment Process to Fit Your Needs; 3 Assembling a Fragment Library; 4 Practical Aspects of Using NMR in Fragment-based Screening; 5 Application of Protein-Ligand NOE Matching to the Rapid Evaluation of Fragment Binding Poses; 6 Target-immobilized NMR Screening: Validation and Extension to Membrane Proteins; 7 In Situ Fragment-based Medicinal Chemistry: Screening by Mass Spectrometry; 8 Computational Approaches to Fragment and Substructure Discovery and Evaluation
9 Virtual Fragment Scanning: Current Trends, Applications and Web-based Tools10 Capture Methods for Fragment-based Discovery; 11 Identification of High-affinity -Secretase Inhibitors Using Fragment-based Lead Generation; Index |
| Record Nr. | UNINA-9910841197103321 |
| Chichester, U.K., : John Wiley & Sons, 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research CNS and neurological disorders . Volume 7 / / edited by Atta-ur-Rahman and Zareen Amtul
| Frontiers in clinical drug research CNS and neurological disorders . Volume 7 / / edited by Atta-ur-Rahman and Zareen Amtul |
| Pubbl/distr/stampa | Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] |
| Descrizione fisica | 1 online resource (166 pages) |
| Disciplina | 615.7 |
| Collana | Frontiers in Clinical Drug Research |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations |
| ISBN | 981-14-4752-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910794360203321 |
| Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research CNS and neurological disorders . Volume 7 / / edited by Atta-ur-Rahman and Zareen Amtul
| Frontiers in clinical drug research CNS and neurological disorders . Volume 7 / / edited by Atta-ur-Rahman and Zareen Amtul |
| Pubbl/distr/stampa | Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] |
| Descrizione fisica | 1 online resource (166 pages) |
| Disciplina | 615.7 |
| Collana | Frontiers in Clinical Drug Research |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations |
| ISBN | 981-14-4752-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910810341003321 |
| Singapore : , : Bentham Science Publishers Pte Ltd., , [2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Frontiers in clinical drug research . Volume 6 CNS and neurological disorders / / edited by Attar-ur-Rahman
| Frontiers in clinical drug research . Volume 6 CNS and neurological disorders / / edited by Attar-ur-Rahman |
| Pubbl/distr/stampa | Sharjah, UAE : , : Bentham Science Publishers, , [2018] |
| Descrizione fisica | 1 online resource (218 pages) |
| Disciplina | 615.7 |
| Soggetto topico |
Biopharmaceutics
Drugs - Design Medical innovations |
| ISBN | 1-68108-607-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910793110103321 |
| Sharjah, UAE : , : Bentham Science Publishers, , [2018] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Drugs - Design
(307)
- Pharmaceutical chemistry (91)
- Drug development (68)
- Drug Design (35)
- Biopharmaceutics (16)